Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
- Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.
- A New School of Drug Discovery
- Profile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers – Published in Nature Reviews Drug Discovery & Nature Biotechnology
- Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome